openPR Logo
Press release

Endometriosis Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Organon, Ironwood Pharma, AbbVie/Neurocrine Biosciences, Mitsubishi Tanabe Pharma Corporation

01-16-2025 07:40 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Endometriosis Pipeline 2024: Detailed Clinical Trials

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Endometriosis pipeline constitutes 15+ key companies continuously working towards developing 20+ Endometriosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Endometriosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Endometriosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Market.

Some of the key takeaways from the Endometriosis Pipeline Report: https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Endometriosis treatment therapies with a considerable amount of success over the years.
• Endometriosis companies working in the treatment market are Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis treatment
• Emerging Endometriosis therapies in the different phases of clinical trials are- Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis market in the coming years.
• In October 2024, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative treatments for advanced solid tumors and other serious diseases, has announced a sponsored research agreement with the University of Cincinnati. The agreement will explore the use of Lisata's novel cyclic peptide product, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for treating endometriosis. While bevacizumab has shown efficacy in treating endometriosis, its high dosage levels can cause systemic side effects, limiting its use in otherwise healthy young women. Lisata will provide funding and certepetide for the research conducted by the University of Cincinnati.
• In March 2024, By the end of this year, Gynica, headquartered in Israel, plans to administer the first dose to a patient in a Phase I trial evaluating its cannabioid-based treatments, IntraVagS301 and IntraVagS302, for endometriosis.

Endometriosis Overview
Endometriosis is a condition where tissue similar to the lining of the uterus (endometrium) grows outside the uterus, often on the ovaries, fallopian tubes, and pelvic tissue. This tissue behaves like the uterine lining, thickening, breaking down, and bleeding with each menstrual cycle, but it has no way to exit the body, leading to inflammation, pain, and sometimes infertility. Common symptoms include pelvic pain, heavy menstrual bleeding, and pain during intercourse or bowel movements. The exact cause is unknown, but factors like genetics, immune system disorders, or hormonal imbalances may contribute. Treatment options include pain management, hormonal therapy, and surgery.

Get a Free Sample PDF Report to know more about Endometriosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Endometriosis Drugs Under Different Phases of Clinical Development Include:
• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical
• MetriDx: Hera Biotech, Inc.
• BG2109: Bio Genuine (Shanghai) Biotech Co., Ltd.
• Relugolix Combination Tablet: Sumitomo Pharma Switzerland GmbH
• FOR 6219: Organon
• IW-3300: Ironwood Pharmaceuticals
• MT-2990: Mitsubishi Tanabe Pharma Corporation
• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
• OVAREST (leuprorelin oral): SWK/Enteris BioPharma
• HMI-115: Bayer/Hope Medicine
• TU2670 (NCE-403): Tiumbio
• OG-6219: Organon
• Quinagolide: Ferring Pharmaceuticals
• Linzagolix: ObsEva

Endometriosis Route of Administration
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Endometriosis Molecule Type
Endometriosis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Endometriosis Pipeline Therapeutics Assessment
• Endometriosis Assessment by Product Type
• Endometriosis By Stage and Product Type
• Endometriosis Assessment by Route of Administration
• Endometriosis By Stage and Route of Administration
• Endometriosis Assessment by Molecule Type
• Endometriosis by Stage and Molecule Type

DelveInsight's Endometriosis Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Endometriosis product details are provided in the report. Download the Endometriosis pipeline report to learn more about the emerging Endometriosis therapies
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Endometriosis Therapeutics Market include:
Key companies developing therapies for Endometriosis are - AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others.

Endometriosis Pipeline Analysis:
The Endometriosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
• Endometriosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Endometriosis drugs and therapies
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Endometriosis Pipeline Market Drivers
• The development of drug delivery systems represents a new approach in pain treatment among endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Market.

Endometriosis Pipeline Market Barriers
• However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Market growth.

Scope of Endometriosis Pipeline Drug Insight
• Coverage: Global
• Key Endometriosis Companies: Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others
• Key Endometriosis Therapies: Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others
• Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
• Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers

Request for Sample PDF Report for Endometriosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Endometriosis Report Introduction
2. Endometriosis Executive Summary
3. Endometriosis Overview
4. Endometriosis- Analytical Perspective In-depth Commercial Assessment
5. Endometriosis Pipeline Therapeutics
6. Endometriosis Late Stage Products (Phase II/III)
7. Endometriosis Mid Stage Products (Phase II)
8. Endometriosis Early Stage Products (Phase I)
9. Endometriosis Preclinical Stage Products
10. Endometriosis Therapeutics Assessment
11. Endometriosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Endometriosis Key Companies
14. Endometriosis Key Products
15. Endometriosis Unmet Needs
16 . Endometriosis Market Drivers and Barriers
17. Endometriosis Future Perspectives and Conclusion
18. Endometriosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Endometriosis Market https://www.delveinsight.com/report-store/endometriosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Endometriosis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:
• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market
• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight
• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Endometriosis Pipeline 2024: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | Organon, Ironwood Pharma, AbbVie/Neurocrine Biosciences, Mitsubishi Tanabe Pharma Corporation here

News-ID: 3818921 • Views:

More Releases from DelveInsight Business Research

IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, PDMA, FDA Approval …
(Albany, USA) DelveInsight's 'IgA Nephropathy Pipeline Insight 2025' report provides comprehensive global coverage of available, marketed, and pipeline IgA nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the IgA nephropathy pipeline domain. IgA nephropathy pipeline report showcase a robust space with 30+ key companies working to develop 30+ pipeline therapies for IgA nephropathy treatment. IgA nephropathy companies
Candidemia Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Candidemia Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, Medi …
(Albany, United States) "Candidemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Candidemia Market. As per DelveInsight's assessment, globally, Candidemia pipeline constitutes 4+ key companies continuously working towards developing 4+ Candidemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Request for Sample Report here @ https://www.delveinsight.com/report-store/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr Some of the key takeaways
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, IND, NDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
CAR T-Cell Therapy for Non-Hodgkin's lymphoma Clinical Trials and Pipeline Analy …
(Albany, United States) "CAR T-Cell Therapy for Non-Hodgkin's lymphoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market. As per DelveInsight's assessment, globally, CAR T-Cell Therapy for Non-Hodgkin's lymphoma pipeline constitutes 5+ key companies continuously working towards developing 5+ CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism
Cystinosis Clinical Trials and Pipeline Assessment: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Cystinosis Clinical Trials and Pipeline Assessment: EMA, PDMA, FDA Approvals, Me …
(Albany, USA) DelveInsight's 'Cystinosis Pipeline Insight 2025' report provides comprehensive global coverage of available, marketed, and pipeline Cystinosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cystinosis pipeline domain. Request for Cystinosis sample pages @ https://www.delveinsight.com/report-store/cystinosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr Key Takeaways from the Cystinosis Pipeline Report • Over 5+ Cystinosis pipeline therapies are in various stages of development, and their anticipated

All 5 Releases


More Releases for Endometriosis

Endometriosis Market Trends, Size, Forecast - 2018-2023
Endometriosis is a painful disorder in which the layer of tissue that normally surfaces inside the uterus, starts growing outside the uterus. This mainly occurs on the fallopian tubes, ovaries, and tissue around the uterus; however, in exceptional cases it may occur in other parts of the body. The endometriosis leads to various physical symptoms such as severe menstrual cramps, nausea and vomiting, fatigue, diarrhea, constipation, long-term pelvic pain, and
Global Endometriosis Market Research and Forecast 2018-2023
Global endometriosis market size, share, market trends, research and analysis report by diagnosis (ultrasound, pelvic exam, laparoscopy, MRI, hysteroscopy, son hysterography) by treatment (hormonal therapy, pain management) forecast 2018-2023 According to the OMR analysis, the global endometriosis market is growing at a significant rate during 2018-2023. The global endometriosis market has been growing significantly due availability of enhanced medications for the disease. The global endometriosis market is segmented on the basis
Endometriosis Therapies Market: Competitive Dynamics & Global Outlook 2023
New report published by Global Info Research which offers insights on the global Endometriosis Therapies market. Therapies used to treat endometriosis include: Hormonal contraceptives. Birth control pills, patches and vaginal rings help control the hormones responsible for the buildup of endometrialtissue each month Click to view the full report TOC, figure and tables: https://www.globalinforesearch.com/global-endometriosis-therapies-market_p87118.html Global Endometriosis Therapies Market: Forecast by Type / Application / Region The worldwide market for
Endometriosis-Pipeline Review H2 2018
Endometriosis-Pipeline Review, H2 2018 Summary Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis-Pipeline Review, H2 2018, provides an overview of the Endometriosis (Women's Health) pipeline landscape. Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment
Global Endometriosis Market Research and Forecast 2018-2023
Endometriosis is a painful disorder in which the layer of tissue that normally surfaces inside the uterus, starts growing outside the uterus. This mainly occurs on the fallopian tubes, ovaries, and tissue around the uterus; however, in exceptional cases it may occur in other parts of the body. The endometriosis leads to various physical symptoms such as severe menstrual cramps, nausea and vomiting, fatigue, diarrhea, constipation, long-term pelvic pain, and
Global Endometriosis Treatment Market has Great Future Ahead
Qyresearchreports include new market research report Global Endometriosis Treatment Market Size,Status and Forecast 2025 to its huge collection of research reports. The comprehensive study on the global Endometriosis Treatment market recently added to our vast repository of market reports is an expansive resource for leading and new companies on the hunt for intelligent information to fabricate production and marketing strategies. The report uncovers insights on the market for Endometriosis Treatment through